Loading company…
Pharos iBio develops treatments for rare diseases using AI-based drug discovery.
Founded in 2016 and based in Anyang-si, South Korea, Pharos iBio develops drugs for rare, incurable diseases using its Chemivesre AI drug discovery platform. Its pipeline includes treatments for acute myeloid leukemia and ovarian cancer. In July 2023, the company raised KRW 19.6 billion in an IPO on the KOSDAQ.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in